Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.94Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Health Score : 5.94Shilpa Medicare Ltd operates within the Healthcare Services sector. The company shows mixed financial results. Growth in revenue and operating profit is a positive sign, alongside a strong solvency position. However, there are some concerns with the company's efficiency and liquidity. The company's profitability metrics are generally strong. The company's financial ratios present a mixed picture, with strengths in book value per share but weaknesses in dividend and capital expenditure management. The company's growth shows positive momentum in certain areas but also highlights significant challenges in earnings and net income. Overall, Shilpa Medicare demonstrates a blend of financial strengths and weaknesses that warrant attention.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
130.84
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
71.52
P/B RATIO
6.74
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
11.51
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
6.67
EV/EBITDA RATIO
37.67
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹889.7 as on Sep 1, 2026.
Growth Score : 6.00The growth ratios show a mixed performance. While revenue and operating profit growth rates are strong, earnings per share (EPS) and net income growth rates are negative. This suggests that the company is growing its top line but struggling to convert it into bottom-line profits. The company has been doing well in terms of revenue and operating profit, but not in terms of earnings.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 26.92 | -8.33 | 9.56 | 11.78 | 20.14 |
| Operating Profit Growth Rate | 11.6 | -50.99 | 141.41 | 32.22 | 37.66 |
| Earnings Per Share (EPS) Growth | -61.48 | -153.58 | 198.4 | 117.39 | 211 |
| Asset Growth Rate | 9.27 | 0.97 | 6.51 | 7.05 | 11.93 |
| Net Income Growth Rate | -58.22 | -150.82 | 203.23 | 143.75 | 211.54 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | SUPRIYA | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | AARTIPHARM | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | INNOVACAP | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | AKUMS | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | MARKSANS | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | AARTIDRUGS | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | HIKAL | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPGLIFE | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | SMSPHARMA | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | SHILPAMED | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | STAR | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | JSLL | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | GUFICBIO | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | DCAL | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | ORCHPHARMA | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | SEQUENT | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | SPARC | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | ZOTA | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | PGHL | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 21 | SANOFI | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Shilpa Medicare Ltd. is a vertically integrated Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Contract Research & Manufacturing Services (CRAMS). With a strong focus on oncology, dermatology, and complex generics, it supplies high-quality products and services to global regulated markets, driven by robust R&D capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Shilpa Medicare Ltd's P/E ratio (TTM) is 130.84, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Shilpa Medicare Ltd's P/B ratio is 6.74, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Shilpa Medicare Ltd's P/S ratio is 11.51, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Shilpa Medicare Ltd's PEG ratio is 6.67.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Shilpa Medicare Ltd's EV/EBITDA ratio is 37.67.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Shilpa Medicare Ltd's ROE is 9.38%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Shilpa Medicare Ltd's ROA is 11.74%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Shilpa Medicare Ltd's ROCE is 11%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Shilpa Medicare Ltd's operating margin is 28.27%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Shilpa Medicare Ltd's net margin is 15.79%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Shilpa Medicare Ltd's current ratio is 1.26.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Shilpa Medicare Ltd's debt-to-equity ratio is 0.08.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Shilpa Medicare Ltd's interest coverage ratio is 6.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Shilpa Medicare Ltd's DPS is ₹0.62.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Shilpa Medicare Ltd's EPS is 211.
(Source line: "Ratios as of 01 Sept 2026, based on last traded price of ₹889.70. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1987 (as Shilpa Antibiotics Pvt. Ltd.)
Headquarters: Raichur, Karnataka
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Contract Research and Manufacturing Services (CRAMS), Biologics, Dermatology products
Stock Listing: NSE (SHILPAMED), BSE (530549)
Promoter: Bhutada Group / Sanghvi Group
1987: Incorporated as Shilpa Antibiotics Pvt. Ltd. 1995: Renamed Shilpa Medicare Ltd. and became a public limited company. Early 2000s: Expanded into oncology API manufacturing, establishing a significant presence. 2005: Listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). 2008: Established an advanced R&D center to support product development. 2013 onwards: Diversified into finished dosage forms, injectables, new drug delivery systems, and biologics through strategic investments and subsidiaries. Present: Operates globally with multiple manufacturing facilities and R&D centers, focusing on complex generics, biosimilars, and innovative drug delivery solutions.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | ~55-65% | Operating Profit |
| Finished Dosage Forms (FDFs) | ~30-35% | Operating Profit |
| Others (CDMO, Biologics) | ~5-10% | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Manufactures a wide spectrum of APIs, with a strong focus on oncology, non-oncology, and highly potent active pharmaceutical ingredients (HPAPIs), serving both regulated and semi-regulated markets globally.
Finished Dosage Forms (FDFs): Develops, manufactures, and markets various finished pharmaceutical products including oral solid dosage forms, injectables, and specialty formulations in therapeutic areas such as oncology, dermatology, and ophthalmology.
Contract Research and Manufacturing Services (CRAMS): Provides comprehensive contract development and manufacturing services for complex molecules, leveraging its R&D capabilities, regulatory expertise, and state-of-the-art manufacturing infrastructure for global clients.
Mr. Omprakash V. Sanghvi (Chairman): A veteran in the pharmaceutical industry, he provides strategic leadership and guidance for the company's long-term vision. Mr. Vishnukant C. Bhutada (Managing Director): An experienced leader, he drives the company's operational efficiency, global expansion, and product development pipeline.
Shilpa Biologicals Pvt. Ltd. (Focuses on biosimilars and biologics development and manufacturing)
Shilpa Pharma Inc. (USA, handles marketing and distribution activities in North America)
Loba Feinchemie GmbH (Germany, specializes in development and manufacturing of intermediates and specialty chemicals)
NuThera Lifesciences (P) Ltd. (Engaged in the development and marketing of nutraceutical products)
Rights Issue in 2021: Issued 4,000,000 equity shares on a 1:4 rights basis at ₹235 per share, aggregating ₹940 million.
The Shilpa Medicare Ltd share price today is ₹889.70 on NSE (SHILPAMED), as of 06 Sept 2026.
As of 01 Sept 2026, Shilpa Medicare Ltd share price is ₹889.70, with previous close ₹889.70. Today's range is ₹889.70 to ₹889.70. The 52-week range is ₹889.70 to ₹889.70.
As of today, Shilpa Medicare Ltd's market cap is ₹17,713.93 crore (Mid Cap).
Shilpa Medicare Ltd's current P/E ratio is 130.84, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.20.
Shilpa Medicare Ltd's current P/B ratio is 6.74.
Shilpa Medicare Ltd's current dividend yield is 0.07%. Last dividend of ₹0.10 per share was declared on 04-Aug-2023.
Shilpa Medicare Ltd's EPS (TTM) is ₹211.
Shilpa Medicare Ltd. is a vertically integrated Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Contract Research & Manufacturing Services (CRAMS). With a strong focus on oncology, dermatology, and complex generics, it supplies high-quality products and services to global regulated markets, driven by robust R&D capabilities.
Shilpa Medicare Ltd is promoted by Bhutada Group / Sanghvi Group, holding 40.13% as of 01 Sept 2026.
Shilpa Medicare Ltd is listed on NSE (SHILPAMED) and BSE (530549). Its next quarterly results are expected on August 2024 (for Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)